Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib + Docetaxel in Advanced NSCLC Previously Treated With Platinum Chemotherapy
NCT00030420Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Oct 2001
- Primary completion
- May 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib oral solution in non-small cell lung cancer (NSCLC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoint: Efficacy of combining Celecoxib with Docetaxel at Week 3. Started Oct 2001; status: completed.
02
Drugs
celecoxib oral solution
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00030420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00030420.